NGS's Principal Activity is the direct sale of products to end customers.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||-19.23%|
|vs ASX 200 (1yr)||-42.62%|
|ASX Rank||2014 of 2,556|
|Sector Rank||69 of 75|
Nutritional Growth Solutions Ltd (NGS) is a global nutritional health company focused on the well-being of children. NGS develops, produces and sells clinically tested nutritional supplement formulae for children following 20 years of medical research into paediatric nutrition at Schneider Children's Medical Centre, Israel's paediatric hospital.
No incorporation details available.
|No dividends paid.|
See Upcoming Dividends for all ASX companies.
|Ms Lisa Wynne||Company Secretary||Dec 2020|
|Ms Liron Fendell||Chief Executive Officer,Managing Director||Oct 2020||
Ms Liron Fendell
Chief Executive Officer,Managing Director
Ms Fendell has experience in nutrition, emerging technology and global child health. Ms Fendell was previously a corporate lawyer in one of Tel Aviv's law firms, representing bio tech start-ups as well as pharmaceutical companies, and gaining experience in structuring, negotiating and executing business transactions. Since 2012, Ms Fendell has served as a board member of CPC - Children Playing Chess, a non-profit organization. Struggling with her own children's nutrition and growth, Ms Fendell joined the Company on its creation in 2014 to work with the founding doctors at Schneider in order to convert the clinical knowledge and data into tangible products and commercial business.
|Dr Kinneret Livnat Savitzky||Non-Executive Director||Oct 2020||
Dr Kinneret Livnat Savitzky
Dr Livnat Savitzky has experience in the life sciences industry, including drug discovery and development, corporate partnering and capital raising. Dr Livnat Savitzky currently serves as the CEO and a board member of FutuRx Ltd., an Israeli biotechnology accelerator established by OrbiMed Israel Partners. Johnson & Johnson Innovation and Takeda Ventures Inc. (the venture group of Takeda Pharmaceutical Company). Dr Livnat Savitzky also serves on the boards of several biotechnology or healthcare companies. From 2010 to 2016. Dr Livnat Savitzky served as the CEO of NASDAQ-listed BioLineRx Ltd. Prior to being appointed CEO of BioLineRx. she held various research and development management positions at BioLineRx and Compugen. She is also member of Risk Committee of the Company.
|Dr Anton Uvarov||Non-Executive Director||Oct 2020||
Dr Anton Uvarov
Dr Uvarov has experience as an advisor to the healthcare industry with a focus on the biotechnology sector both in Australia and internationally, and has been involved in funding numerous biotechnology and pharmaceutical companies. He is a former equities research analyst with Citigroup, US. Dr Uvarov is a founding director of Actinogen Medical (ASX:ACW), a clinical stage biotechnology company and is an Executive Director of Neuroscientific Biopharmaceuticals (ASX:NSB), a biotechnology company developing new treatments for neurodegenerative diseases. Dr Uvarov is a former Director of Elsight Limited (ASX:ELS) and Parazero Limited (ASX:PRZ). He is also member of Risk Committee of the Company.
|Mr Amir Zaidman||Non-Executive Director||Oct 2020||
Mr Amir Zaidman
Mr Zaidman has more than 20 years of experience in business development and venture capital investments. Since 2014, Mr Zaidman has served as the vice president of business development of "The Kitchen Hub" - the first FoodTech focused seed investor and technology incubator in Israel. In this capacity he provides business development and marketing support to portfolio companies and is also in charge of The Kitchen Hub's new investments, and has led the investment process in 18 portfolio companies to date. Mr Zaidman serves on the board of directors of numerous private FoodTech companies. Mr Zaidman is a executive in the FoodTech community in Israel. He created and manages the Israel FoodTech Innovation Linkedln group as well as the Israel's FoodTech Community MeetUp group. He is also Chair of Risk Committee of the Company.
|Mr Brian Willoughby Leedman||Non-Executive Chairman,Non-Executive Director||Sep 2020||
Mr Brian Willoughby Leedman
Non-Executive Chairman,Non-Executive Director
Mr Leedman is a marketing and investor relations executive with over 15 years of experience in the biotechnology I healthcare industry. He is the founder of ResApp Diagnostics Pty Ltd which was acquired by Narhex Life Sciences Ltd to form ResApp Health (ASX:RAP) and Chairman of Neuroscientific Biopharmaceuticals (ASX:NSB). Previously, Mr Leedman co-founded Oncosil Medical Limited (ASX:OSL) and Biolife Science Limited (which was subsequently acquired by Imugene Limited (ASX:IMU)).Mr Leedman also served for ten years as Vice President (Investor Relations) at pSivida Corp, (now called Eyepoint Pharmaceuticals (NASDAQ:EYPT)). He was the Western Australian Chairman of AusBiotech, the association of biotechnology companies in Australia and formerly a non-executive Director at Alcidion Limited (ASX:ALC). Mr Leedman is a past winner of the 40Under40 Business Awards and represented ResApp Health as the global winner of Best Tech IPO' at the 2016 Talent Unleashed Awards culminating in spending a week in Silicon Valley with a judge for the Talent Unleashed Awards and the co-founder of Apple Corp., Steve Wozniak.
|Professor Raanan Shamir||Chief Medical Officer,Executive Director||Jan 2014||
Professor Raanan Shamir
Chief Medical Officer,Executive Director
Prof Shamir is Chairman of the Institute of Gastroenterology, Nutrition and Liver Diseases at Schneider. In the early 90s, he was a fellow at the Division of Pediatric Gastroenterology and Nutrition at The Children's Hospital of Philadelphia. Prof Shamir has published approximately 400 original papers, reviews and comments, book chapters and guidelines. His current research areas include paediatric nutrition, nutrition and growth, celiac disease, inflammatory bowel disease and childhood hyperlipidemia. Prof Shamir is a co-founder of the Company.
The current holdings of NGS directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
|Kinneret Livnat Savitzky||28/10/2020||0||N/A||N/A||N/A|
No Substantial Shareholders for NGS in our database.
12 month transaction history compiled from ASX announcements.
No buy transactions reported by Substantial Shareholders in the past 12 months.
12 month transaction history compiled from ASX announcements.
No sell transactions reported by Substantial Shareholders in the past 12 months.
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.